Mersana Therapeutics (MRSN) Stock Forecast & Price Target

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

$3.79

-0.02 (-0.52%)

(As of 04/15/2024 ET)

Mersana Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$6.29
65.85% Upside

High Forecast	$9.00
Average Forecast	$6.29
Low Forecast	$5.00

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	1 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	5 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$6.29	$6.29	$7.17	$14.71
Predicted Upside	65.85% Upside	45.42% Upside	108.64% Upside	177.15% Upside

Get Mersana Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

MRSN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRSN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mersana Therapeutics Stock vs. The Competition

Type	Mersana Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.68	2.48
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	65.85% Upside	882.04% Upside	11.23% Upside
News Sentiment Rating	Very Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral	$5.00	+2.88%
2/29/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$9.00	+85.57%
2/29/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$1.00 ➝ $5.00	+3.09%
2/29/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$6.00	+23.71%
2/29/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$7.00	+44.33%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.00 ➝ $7.00	+44.33%
12/4/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$1.00 ➝ $5.00	+163.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:09 AM ET.

MRSN Price Target - Frequently Asked Questions

What is Mersana Therapeutics's consensus rating and price target?: According to the issued ratings of 7 analysts in the last year, the consensus rating for Mersana Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 5 buy ratings for MRSN. The average twelve-month price prediction for Mersana Therapeutics is $6.29 with a high price target of $9.00 and a low price target of $5.00. Learn more on MRSN's analyst rating history.
Do Wall Street analysts like Mersana Therapeutics more than its competitors?: Analysts like Mersana Therapeutics more than other Medical companies. The consensus rating score for Mersana Therapeutics is 2.71 while the average consensus rating score for medical companies is 2.68. Learn more on how MRSN compares to other companies.
Is Mersana Therapeutics being upgraded by Wall Street analysts?: Over the previous 90 days, Mersana Therapeutics's stock had 5 upgrades by analysts.

Does Mersana Therapeutics's stock price have much upside?: According to analysts, Mersana Therapeutics's stock has a predicted upside of 41.89% based on their 12-month stock forecasts.
What analysts cover Mersana Therapeutics?: Mersana Therapeutics has been rated by BTIG Research, Guggenheim, JPMorgan Chase & Co., Robert W. Baird, Truist Financial, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:MRSN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mersana Therapeutics (MRSN) Stock Forecast & Price Target

Mersana Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

MRSN Analyst Ratings By Month

MRSN Price Targets by Month

Mersana Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

MRSN Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info